94 related articles for article (PubMed ID: 1359204)
1. Biological markers and minimal residual disease in hairy cell leukemia.
Lauria F; Raspadori D; Benfenati D; Rondelli D; Pallotti A; Tura S
Leukemia; 1992 Nov; 6 Suppl 4():149-51. PubMed ID: 1359204
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
3. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
6. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
Arun B; Curti BD; Longo DL; Stevens D; Alvord WG; Gause BL; Watson T; Kopp WC; Janik JE
Cancer J Sci Am; 2000; 6(1):21-4. PubMed ID: 10696734
[TBL] [Abstract][Full Text] [Related]
7. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
[TBL] [Abstract][Full Text] [Related]
9. Long-term results in hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Chrobák L; Zák P; Podzimek K; Plísková L; Foglová J; Maisnar V; Dulícek P; Dĕdic K
Acta Medica (Hradec Kralove); 1997; 40(2):41-5. PubMed ID: 9389210
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-1 beta levels correlate with neoplastic bulk in hairy cell leukemia.
Cimino G; Annino L; Giona F; Sgadari C; Di Gregorio AO; Cava MC; Cimino G; Mandelli F
Leukemia; 1991 Jul; 5(7):602-5. PubMed ID: 2072745
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients.
Cimino G; Amadori S; Cava MC; De Sanctis V; Petti MC; Di Gregorio AO; Sgadari C; Vegna L; Cimino G; Mandelli F
Leukemia; 1991 Jan; 5(1):32-5. PubMed ID: 1999955
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of complete remission in hairy cell leukemia patients treated with alpha-IFN.
Lauria F; Foà R; Raspadori D; Pileri S; Tassinari A; Buzzi M; Zaccaria A; Zinzani PL; Tura S
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():176-8. PubMed ID: 2785426
[TBL] [Abstract][Full Text] [Related]
13. [Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment].
Urasiński I; Zdziarska B; Krygier-Stojałowska A
Acta Haematol Pol; 1996; 27(1):49-55. PubMed ID: 8629443
[TBL] [Abstract][Full Text] [Related]
14. High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Lauria F; Benfenati D; Raspadori D; Rondelli D; Zinzani PL; Tura S
Leuk Lymphoma; 1993 Nov; 11(5-6):399-404. PubMed ID: 7907247
[TBL] [Abstract][Full Text] [Related]
15. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia.
Barak V; Nisman B; Polliack A; Vannier E; Dinarello CA
Eur Cytokine Netw; 1998 Mar; 9(1):33-9. PubMed ID: 9613675
[TBL] [Abstract][Full Text] [Related]
16. Hairy cell leukaemia, its therapy and prognosis (historical review with own experiences).
Chrobák L; Podzimek K; Zak P; Plísková L; Voglová J
Acta Haematol Pol; 1995; 26(2 Suppl 1):56-62. PubMed ID: 7653236
[TBL] [Abstract][Full Text] [Related]
17. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
18. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
19. The tumor necrosis factor family and and correlation with disease activity and response to treatment in hairy cell leukemia.
Barak V; Nisman B; Polliack A
Eur J Haematol; 1999 Feb; 62(2):71-5. PubMed ID: 10052708
[TBL] [Abstract][Full Text] [Related]
20. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
